Display options
Cite
Skrzydło-Radomańska B, Radwan P. Dexlansoprazole - a new-generation proton pump inhibitor. Prz Gastroenterol. 2015;10(4):191-6doi: 10.5114/pg.2015.56109.
Skrzydło-Radomańska, B., & Radwan, P. (2015). Dexlansoprazole - a new-generation proton pump inhibitor. Przeglad gastroenterologiczny, 10(4), 191-6. https://doi.org/10.5114/pg.2015.56109
Skrzydło-Radomańska, Barbara, and Radwan, Piotr. "Dexlansoprazole - a new-generation proton pump inhibitor." Przeglad gastroenterologiczny vol. 10,4 (2015): 191-6. doi: https://doi.org/10.5114/pg.2015.56109
Skrzydło-Radomańska B, Radwan P. Dexlansoprazole - a new-generation proton pump inhibitor. Prz Gastroenterol. 2015;10(4):191-6. doi: 10.5114/pg.2015.56109. Epub 2015 Dec 16. PMID: 26759624; PMCID: PMC4697039.
Copy Download .nbib Format: NLM
Share it on

Prz Gastroenterol. 2015;10(4):191-6. doi: 10.5114/pg.2015.56109. Epub 2015 Dec 16.

Dexlansoprazole - a new-generation proton pump inhibitor.

Przeglad gastroenterologiczny

Barbara Skrzydło-Radomańska, Piotr Radwan

Affiliations

  1. Chair and Department of Gastroenterology, Medical University of Lublin, Lublin, Poland.

PMID: 26759624 PMCID: PMC4697039 DOI: 10.5114/pg.2015.56109

Abstract

Dexlansoprazole modified release (MR) is an R-enantiomer of lansoprazole and a new-generation proton pump inhibitor exhibiting high efficacy in the treatment of symptoms and lesions associated with erosive oesophagitis caused by gastroesophageal reflux disease (GERD). The dual release of the active ingredient - in the duodenum and the small intestine - makes it possible to achieve two peak concentrations at various times, within two and five hours of administration. Dexlansoprazole MR ensures the longest maintenance of drug concentration in the plasma of all known proton pump inhibitors, and the longest proton pump inhibitory effect. The basic indications for the drug include all forms of gastroesophageal reflux disease, especially with night-time heartburn and sleep disorders resulting from GERD. Dexlansoprazole can be taken regardless of meal times. It has a good safety profile and carries a low risk of adverse interactions with other drugs.

Keywords: R-enantiomer; dexlansoprazole; proton pump inhibitor; treatment of gastroesophageal reflux disease

References

  1. Aliment Pharmacol Ther. 2006 May 15;23(10):1473-7 - PubMed
  2. Aliment Pharmacol Ther. 2009 Jun 15;29(12):1261-72 - PubMed
  3. Clin Exp Gastroenterol. 2011;4:213-20 - PubMed
  4. Gastroenterology. 2008 Oct;135(4):1392-1413, 1413.e1-5 - PubMed
  5. Aliment Pharmacol Ther. 2009 Nov 15;30(10):1010-21 - PubMed
  6. Aliment Pharmacol Ther. 2009 Apr 1;29(7):731-41 - PubMed
  7. Clin Gastroenterol Hepatol. 2012 Mar;10(3):247-53 - PubMed
  8. Drugs. 2008;68(7):925-47 - PubMed
  9. J Pediatr Gastroenterol Nutr. 2012 Jan;54(1):41-7 - PubMed
  10. Arq Bras Cir Dig. 2014 Jul-Sep;27(3):210-5 - PubMed
  11. Dig Dis Sci. 2010 Dec;55(12):3415-22 - PubMed
  12. Aliment Pharmacol Ther. 2011 Feb;33(3):366-77 - PubMed
  13. Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):439-45 - PubMed
  14. Aliment Pharmacol Ther. 2013 Jul;38(2):190-201 - PubMed
  15. Aliment Pharmacol Ther. 2010 May;31(9):1001-11 - PubMed
  16. Aliment Pharmacol Ther. 2007 Aug 1;26(3):443-52 - PubMed
  17. Drug Saf. 2006;29(9):769-84 - PubMed
  18. Aliment Pharmacol Ther. 2001 Oct;15(10):1563-9 - PubMed
  19. Ann Pharmacother. 2010 May;44(5):871-7 - PubMed
  20. Clin Gastroenterol Hepatol. 2015 May;13(5):859-66.e1 - PubMed
  21. Aliment Pharmacol Ther. 2009 Apr 1;29(7):742-54 - PubMed
  22. Aliment Pharmacol Ther. 2009 Apr 15;29(8):824-33 - PubMed
  23. Clin Exp Gastroenterol. 2014 Dec 08;7:461-71 - PubMed
  24. Dig Dis. 2007;25(3):172-4 - PubMed
  25. Scand J Gastroenterol. 2012 Jul;47(7):751-61 - PubMed
  26. Ann Med. 2011 Aug;43(5):366-74 - PubMed
  27. Crit Care. 2005 Feb;9(1):45-50 - PubMed
  28. Pharm Res. 1996 Apr;13(4):611-5 - PubMed
  29. Drugs. 2003;63(24):2739-54 - PubMed
  30. Anesth Analg. 2005 Oct;101(4):1038-41, table of contents - PubMed

Publication Types